Barliz Waissengrin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7318158/publications.pdf

Version: 2024-02-01

1478505 996975 21 401 15 6 citations h-index g-index papers 23 23 23 825 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncology, The, 2021, 22, 581-583.	10.7	158
2	Rapid Implementation of Telemedicine During the COVID-19 Pandemic: Perspectives and Preferences of Patients with Cancer. Oncologist, 2021, 26, e679-e685.	3.7	75
3	Patterns of Use of Medical Cannabis Among Israeli Cancer Patients: A Single Institution Experience. Journal of Pain and Symptom Management, 2015, 49, 223-230.	1.2	64
4	Breaking Bad News via Telemedicine: A New Challenge at Times of an Epidemic. Oncologist, 2020, 25, e879-e880.	3.7	44
5	Use of medical cannabis: perceptions of Israeli oncologists. Lancet Oncology, The, 2019, 20, 475-477.	10.7	20
6	Effect of cannabis on oxaliplatin-induced peripheral neuropathy among oncology patients: a retrospective analysis. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199020.	3.2	19
7	Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian Cancer. Oncologist, 2021, 26, 30-39.	3.7	8
8	Breast cancer incidence in BRCA mutation carriers with ovarian cancer: A longitudal observational study. Gynecologic Oncology, 2021, 162, 715-719.	1.4	3
9	Perception of patients regarding telemedicine at times of COVID-19: Did they miss the personal touch?. Journal of Clinical Oncology, 2020, 38, 260-260.	1.6	3
10	Knowledge, attitude and practices regarding use of medical cannabis: A national survey among israeli oncologists Journal of Clinical Oncology, 2019, 37, e23110-e23110.	1.6	2
11	The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer Journal of Clinical Oncology, 2021, 39, e12505-e12505.	1.6	1
12	Verification of statistical oncological endpoints on encrypted data: Confirming the feasibility of real-world data sharing without the need to reveal protected patient information Journal of Clinical Oncology, 2021, 39, e18725-e18725.	1.6	1
13	Chemotherapy at the end of life: Do we know when to stop?. Journal of Clinical Oncology, 2021, 39, e24005-e24005.	1.6	1
14	Universal health insurance does not protect from financial burden: A survey of Israeli cancer patients Journal of Clinical Oncology, 2018, 36, e18898-e18898.	1.6	1
15	Knowledge, attitude and practices regarding the use of medical cannabis: A national survey among Israeli oncologists Journal of Clinical Oncology, 2020, 38, e24125-e24125.	1.6	1
16	In Reply. Oncologist, 2020, 25, e1817.	3.7	0
17	Comparing implementation of Telemedicine compliance and feasibility among oncology patients across countries during the COVID 19 pandemic Journal of Clinical Oncology, 2021, 39, e13622-e13622.	1.6	O
18	Assessment of breast cancer risk in BRCA carriers with ovarian cancer: Evaluation of data from longitudinal observation Journal of Clinical Oncology, 2019, 37, e13062-e13062.	1.6	O

#	Article	IF	CITATIONS
19	Saving the best to the last: Can we wait for second-line?. Journal of Clinical Oncology, 2020, 38, 284-284.	1.6	O
20	Less Is More: Polypharmacy at the End of Life. Israel Medical Association Journal, 2021, 23, 452-453.	0.1	0
21	The use of medical cannabis concomitantly with immune-check point inhibitors (ICI) in non-small cell lung cancer (NSCLC): A sigh of relief?. Journal of Clinical Oncology, 2022, 40, e21097-e21097.	1.6	O